Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma.
Joshua Richter, MD, an assistant professor of medicine, and a hematologist/oncologist at Mount Sinai Hospital, discusses the importance of optimizing available therapies in multiple myeloma.
Historically, multiple myeloma was thought to be an incurable disease, says Richter. However, multiple advances in the field have pushed the field closer to developing a cure for patients.
In addition to conducting more clinical trials and evaluating novel regimens, it is necessary to optimize available therapies, Richter adds.
Utilizing a multiomic approach may allow the field to optimize existing approaches, and provide precision medicine to patients with multiple myeloma, Richter concludes.